炎症性肠病中硫嘌呤与抗肿瘤坏死因子治疗相关的急性动脉事件复发风险
基于法国全国健康保险数据库的队列研究,纳入27,185例有急性动脉事件史的炎症性肠病患者,随访至2018年12月31日。抗肿瘤坏死因子暴露与急性动脉事件复发风险降低相关(HR 0.75,95%CI 0.63-0.90),硫嘌呤暴露亦与风险降低相关(HR 0.76,95%CI 0.66-0.88)。
要点
- 有急性动脉事件史的炎症性肠病患者中,抗肿瘤坏死因子暴露与复发风险降低相关(HR 0.75)。
- 硫嘌呤暴露同样与急性动脉事件复发风险降低相关(HR 0.76)。
- 该研究为全国性队列,随访期间每1000人年急性动脉事件复发率为56.4。
核心结论
- 在有急性动脉事件史的炎症性肠病患者中,抗肿瘤坏死因子和硫嘌呤暴露均与急性动脉事件复发风险降低相关。
研究设计与样本
- 基于法国全国健康保险数据库的全国性队列研究,纳入有急性动脉事件史的炎症性肠病患者,随访时间为2009年1月1日至2018年12月31日。
- 共纳入27,185例患者,总随访121,822人年,中位随访期4.0年。
- 采用边际结构Cox比例风险模型,校正基线和时变协变量。
主要发现
- 随访期间共发生6,865例次急性动脉事件复发,发病率为每1000人年56.4(95%CI 55.0-57.7)。
- 与未暴露于任一治疗相比,抗肿瘤坏死因子暴露与急性动脉事件复发风险降低相关(HR 0.75,95%CI 0.63-0.90)。
- 与未暴露于任一治疗相比,硫嘌呤暴露与急性动脉事件复发风险降低相关(HR 0.76,95%CI 0.66-0.88)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with inflammatory bowel disease (IBD) are at increased risk of acute arterial events. Treatment with anti-tumor necrosis factor (anti-TNF) agents has been associated with a protective effect against the first occurrence of acute arterial events, but the impact of treatment with anti-TNF in patients with a previous history of acute arterial events remains unclear. We assessed the effect of anti-TNF and thiopurines on the risk of recurrent acute arterial events in patients with IBD in a nationwide cohort. METHODS: Based on the French nationwide health insurance database, patients with IBD and a previous history of an acute arterial event were followed up from January 1, 2009, until December 31, 2018. The risk of acute arterial event recurrence associated with anti-TNF and thiopurine exposure was assessed using marginal structural Cox proportional hazard models adjusted for baseline and time-varying covariates. RESULTS: A total of 27,185 patients were included. During 121,822 person-years (median follow-up period, 4.0 y), 6865 recurrent acute arterial events occurred (incidence rate per 1000 person-years, 56.4; 95% CI, 55.0-57.7). Exposure to both anti-TNF and thiopurines were associated with a decreased risk of recurrent acute arterial events compared with the absence of exposure to either treatment (hazard ratio, 0.75; 95% CI, 0.63-0.90 and hazard ratio, 0.76; 95% CI, 0.66-0.88, respectively). CONCLUSIONS: In a nationwide cohort study of patients with IBD and a previous history of an acute arterial event, exposure to both anti-TNF and thiopurines were associated with a decreased risk of recurrent acute arterial events.
引用
- Dheyriat L, Ward D, Beaugerie L, et al. Risk of Recurrent Acute Arterial Events Associated With Thiopurines and Anti-Tumor Necrosis Factor in Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2022. PMID: 35842123. doi:10.1016/j.cgh.2022.06.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。